Ceftaroline (original) (raw)

• Centers for Disease Control and Prevention. S. aureus and MRSA Surveillance Summary 2007. Department of Health and Human Services, Centres for Disease Control and Prevention October 17, 2007 [online]. Available from URL: http://www.cdc.gov/ncidod/dhqp/ar_mrsa_surveillanceFS.html [Accessed 2008 May 22]
• Klevens RM, Edwards JR, Tenover FC, et al. National Nosocomial Infections Surveillance System. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992–2003. Clin Infect Dis 2006 Feb; 42(3): 389–91
  Google Scholar
• Conly J. Antimicrobial resistance in Canada. CMAJ 2002 Oct 15; 167(8): 885–91
  PubMed Google Scholar
• CNISP PCSIN. Surveillance for methicillin-resistant Staphylococcus aureus (MRSA) 2006 results. Canadian Nosocomial Infection Surveillance Program (CNISP), Public Health Agency of Canada 2006 [online]. Available from URL: http://www.phac-aspc.gc.ca/nois-sinp/projects/pdf/mrsa_report2006-eng.pdf [Accessed 2008 May 26]
• Canadian Nosocomial Infection Surveillance Program. Surveillance for methicillin-resistant Staphylococcus aureus in Canadian hospitals: a report update from the Canadian Nosocomial Infection Surveillance Program. Can Commun Dis Rep 2005 Feb; 31(3): 33–9
  Google Scholar
• Tiemersma EW, Bronzwaer SL, Lyytikäinen O, et al. European Antimicrobial Resistance Surveillance System Participants. Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis 2004 Sep; 10(9): 1627–34
  Google Scholar
• Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002–2006. Clin Infect Dis 2008 Mar; 46(5): 668–74
  Article PubMed CAS Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009 Jan; 66(1): 82–98
  Article PubMed CAS Google Scholar
• Vardakas KZ, Ntziora F, Falagas ME. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother 2007 Oct; 8(14): 2381–400
  Article PubMed CAS Google Scholar
• Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002 Aug; 46(8): 2723–6
  Article PubMed CAS Google Scholar
• Talbot GH, Thye D, Das A, et al. Phase 2 study of ceftaro-line versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007 Oct; 51(10): 3612–6
  Article PubMed CAS Google Scholar
• van Bambeke F, Mingeot-Leclercq MP, Struelens MJ, et al. The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends Pharmacol Sci 2008 Mar; 29(3): 124–34
  Article PubMed Google Scholar
• Zhanel GG, Karlowsky JA, Rubinstein E, et al. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther 2006 Feb; 4(1): 9–25
  Article PubMed CAS Google Scholar
• Poulakou G, Giamarellou H. Investigational treatments for postoperative surgical site infections. Expert Opin Investig Drugs 2007 Feb; 16(2): 137–55
  Article PubMed CAS Google Scholar
• Corey R, Wilcox M, Talbot GH, et al. CANVAS-1: randomized, double-blinded, phase 3 study (P903-06) of the efficacy and safety of ceftaroline vs vancomycin plus aztreonam in complicated skin and skin structure infections (cSSSI) [abstract no. L-1515a]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting; 2008 Oct 25–28; Washington, DC
• Patrick G. An introduction to medicinal chemistry. 3rd ed. Oxford: Oxford University Press, 2005
  Google Scholar
• Parish D, Scheinfeld N. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr Opin Investig Drugs 2008 Feb; 9(2): 201–9
  PubMed CAS Google Scholar
• Ishikawa T, Matsunaga N, Tawada H, et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003 May; 11(11): 2427–37
  Article PubMed CAS Google Scholar
• Page MGP. Emerging cephalosporins. Expert Opin Emerg Drugs 2007 Nov; 12(4): 511–24
  Article PubMed CAS Google Scholar
• Ikeda Y, Ban J, Ishikawa T, et al. Stability and stabilization studies of TAK-599 (ceftaroline fosamil), a novel N-phosphono type prodrug of anti-methicillin resistant Staphylococcus aureus cephalosporin T-91825. Chem Pharm Bull (Tokyo) 2008 Oct; 56(10): 1406–11
  Article CAS Google Scholar
• Villegas-Estrada A, Lee M, Hesek D, et al. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA β-lactam antibiotics. J Am Chem Soc 2008 Jul; 130(29): 9212–3
  Article PubMed CAS Google Scholar
• Moisan H, Pruneau M, Malouin F. Binding of ceftaroline (CPT) to penicillin-binding proteins (PBPs) of Streptococcus pneumoniae (SPN) and methicillin-resistant Staphylococcus aureus (MRSA) [abstract no. C1-183]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting; 2008 Oct 25–28; Washington, DC
• Hesek D, Suvorov M, Morio K, et al. Synthetic peptidoglycan substrates for penicillin-binding protein 5 of Gram-negative bacteria. J Org Chem 2004 Feb; 69(3): 778–84
  Article PubMed CAS Google Scholar
• Mushtaq S, Warner M, Ge Y, et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007 Aug; 60(2): 300–11
  Article PubMed CAS Google Scholar
• Hinshaw RR, Schaadt RD, Murray B, et al. Spontaneous mutation frequency and serial passage resistance development studies with ceftaroline (CPT) [abstract no. C1-185]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting; 2008 Oct 25–28; Washington, DC
• Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009 Mar; 53(3): 1271–4
  Article PubMed CAS Google Scholar
• Ge Y, Blosser RS, Sahm D, et al. In vitro activity of T-91825, a new anti-MRSA cephalosporin, against Gram-positive and Gram-negative clinical isolates. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago (IL)
• Ge Y, Thye DA, Talbot GH. In vitro activity of ceftaroline against isolates from patients with complicated skin and skin structure infections (cSSSI) [abstract no. C2-864]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
• Ge Y, Biek D, Talbot G, et al. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008 Sep; 52(9): 3398–407
  Article PubMed CAS Google Scholar
• Iizawa Y, Nagai J, Ishikawa T, et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004 Jun; 10(3): 146–56
  Article PubMed CAS Google Scholar
• Kaniga K, Redman R, Pecoraro ML, et al. Antibacterial activity of PPI-0903 against isolates from patients with complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and hospital-acquired pneumonia (HAP) [abstract no. F-1159]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16–19; Washington, DC
• McGee L, Biek D, Ge Y, et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemotherapy 2009; 53: 552–6
  Article CAS Google Scholar
• Morrissey I, Curry J, Ge Y, et al. The activity of ceftaroline against community-acquired pneumonia (CAP) bloodstream isolates [abstract no. E-281]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
• Sader HS, Moet GJ, Fritsche TR, et al. Evaluation of the bactericidal activity of the novel cephalosporin ceftaroline (PPI-0903M) compared to ceftriaxone against Streptococcus pneumoniae [abstract no. E-121]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)
• Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008 Mar; 52(3): 1153–5
  Article PubMed CAS Google Scholar
• Sader HS, Fritsche TR, Kaniga K, et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005 Aug; 49(8): 3501–12
  Article PubMed CAS Google Scholar
• Jones RN, Fritsche TR, Sader HS. Ceftaroline activity tested against organisms causing skin and skin structure infections (SSSI) isolated in USA and European medical centers in 2008 [abstract no. C1-160]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting; 2008 Oct 25–28; Washington, DC
• Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of ceftaroline (CPT) tested against contemporary (2008) bacteria isolated from community-acquired respiratory tract infections, including oxacillin-(methicillin-) resistant Staphylococcus aureus (MRSA) [abstract no. C2-1974]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting; 2008 Oct 25–28; Washington, DC
• Patel SN, McGeer A, Green K, et al. Activities of ceftaroline, ceftobiprole, and cethromycin against multidrug resistant (MDR) Streptococcus pneumoniae isolates from Canadian Bacterial Surveillance Network (CBSN) [abstract no. C1-3843]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting; 2008 Oct 25–28; Washington, DC
• Barry PM, Lenderman CJ, Melendez JH, et al. In vitro activity of ceftaroline (CPT) against recent US isolates of Neisseria gonorrhoeae (NG) [abstract no. C1-163]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting; 2008 Oct 25–28; Washington, DC
• Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline (CPT) vs vancomycin (VM) against MRSA and hVISA strains in a pharmacokinetic/pharmacodynamic (PK/PD) model [abstract no. A-979]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting; 2008 Oct 25–28; Washington, DC
• Saravolatz LD, Pawlak J, Johnson L. In vitro activity of ceftaroline against CA-MRSA, VISA, VRSA, and daptomycin-non-susceptible Staphylococcus aureus (DNSSA) [abstract no. C1-162]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting; 2008 Oct 25–28; Washington, DC
• Fenoll A, Aguilar L, Robledo O, et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother 2008; 52: 4209–10
  Article PubMed CAS Google Scholar
• Jones RN, Fritsche TR, Ge Y, et al. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005 Dec; 56(6): 1047–52
  Article PubMed CAS Google Scholar
• Sader HS, Moet G, Fritsche TR, et al. Evaluation of the bactericidal activity of the novel cephalosporin ceftaroline (PPI-0903M) compared to ceftriaxone against Streptococcus pneumoniae [abstract no. E-0121]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sept 27–30; San Francisco (CA)
• Citron DM, Goldstein EJC. Effects of in vitro test method variables on ceftaroline activity against aerobic Gram-positive and Gram-negative pathogens [abstract no. D-2232]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America; 2008 Oct 25–28; Washington, DC
• Schaadt R, Sweeney D, Biek D, et al. The in vitro activity of ceftaroline in combination with other antibacterial agents [abstract no. E-279]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
• Vidaillac C, Leonard SN, Sader HS, et al. In vitro activity of ceftaroline (CPT) in combination against extended-spectrum β-lactamase (ESBL) producing Gram-negative bacteria (GN) [abstract no. C1-161]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting; 2008 Oct 25–28; Washington, DC
• Vidaillac C, Leonard SN, Rybak MJ. In vitro activity and aminoglycoside synergy of ceftaroline (CPT) against clinical isolates of hospital-acquired (HA) methicillin-resistant Staphylococcus aureus (MRSA) [abstract no. C1-3719]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting 2008 Oct 25–28; Washington, DC
• Ge Y, Floren L, Redman R, et al. Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects [abstract no. A-1936]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)
• Ge Y, Redman R, Floren L, et al. The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions [abstract no. A-1937]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)
• Riccobene T, Fang E, Thye D. A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (IM) injection to healthy subjects [abstract no. A-1888]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America; 2008 Oct 25–28; Washington, DC
• Ge Y, Thye D, Liao S, et al. Pharmacokinetics (PK) of ceftaroline (PPI0903) in subjects with mild or moderate renal impairment (RI) [abstract no. A-1939]. 46th Inter-science Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)
• Ge Y, Liao S, Talbot GH. Population pharmacokinetics (PK) analysis of ceftaroline (CPT) in volunteers and patients with complicated skin and skin structure infection (cSSSI) [abstract no. A-34]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
• Ge Y, Hubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903) [abstract no. A-1935]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)
• Jacqueline C, Caillon J, Miegeville A, et al. Penetration of ceftaroline (PPI-0903), a new cephalosporin, into lung tissues: measurement of plasma and lung tissue concentrations after a short IV infusion in the rabbit [abstract no. A-1938]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)
• Ge Y, Liao S, Thye DA, et al. Ceftaroline (CPT) Dose adjustment recommendations for subjects with mild or moderate renal impairment (RI) [abstract no. A-35]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
• Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006 Apr; 50(4): 1376–83
  Article PubMed CAS Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1–10
  Article PubMed CAS Google Scholar
• Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 2004; 2: 289–300
  Article PubMed CAS Google Scholar
• Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007 Sep; 51(9): 3397–400
  Article PubMed CAS Google Scholar
• Jacqueline C, Caillon J, Amador G, et al. In vivo assessment of the activity of ceftaroline, linezolid, and vancomycin in a rabbit osteomyelitis experimental model due to MRSA and GISA [poster no. 128-E]. American College of Clinical Pharmacy; 2008 Oct 19–22; Louisville (KY)
• Xiong YQ, Li Y, Abdelsayed GA, et al. Real-time evaluation of ceftaroline (CPT), a new cephalosporin, vs vancomycin (VAN), and daptomycin (DAP) in a rat Staphylococcus aureus endocarditis model using in vivo bioluminescent imaging [abstract no. B-819]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
• Jacqueline C, Caillon J, LeMabecque V, et al. Evaluation of the efficacy of intramuscular (IM) administration of ceftaroline (CPT) against a methicillin-resistant Staphylococcus aureus (MRSA) strain in a rabbit endocarditis model (REM) [abstract no. B-1003]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting; 2008 Oct 25–28; Washington, DC
• Jacqueline C, Amador G, Batard E, et al. Assessment of the in vivo activity of ceftaroline (CPT) against vancomycin-susceptible and -resistant Enterococcus faecalis (EF) strains in a rabbit endocarditis model (REM): comparison with linezolid (LZO) and vancomycin (VAN) [abstract no. B-068]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting; 2008 Oct 25–28; Washington, DC
• Forest Laboratories Inc. Forest Laboratories announces positive results from phase III clinical studies of ceftaroline for the treatment of complicated skin and skin structure infections. Press release 2008 Jun 19 [online]. Available from URL: http://www.frx.com/news/PressRelease.aspx?ID=1167784 [Accessed 2008 Jul 11]
• Levasseur P, Girard AM, Delachaume C, et al. NXL104, a novel β-lactamase inhibitor, restores the bactericidal activity of ceftazidime against ESBL and AmpC producing strains of Enterobacteriaceae [abstract no. F-127]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)
• Miossec C, Poirel L, Livermore D, et al. In vitro activity of the new β-lactamase inhibitor NXL104: restoration of ceftazidime (CAZ) efficacy against carbapenem-resistant Enterobacteriaceae strains [abstract no. F1-318]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
• Mushtaq S, Warner M, Miossec C, et al. NXL104/cephalosporin combinations vs. Enterobacteriaceae with CTX-M ESBLs [abstract no. F1-319]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
• Novexel and Forest Laboratories Inc. Novexel and Forest Laboratories announce license agreement for NXL 104, a novel broad-spectrum beta-lactamase inhibitor. Press release 2008 Jan 22 [online]. Available from URL: http://www.reuters.com/article/pressRelease/idUS133612+22-Jan-2008+PRN20080122 [Accessed 2008 Jul 11]
• Novexel. Novexel’s NXL104/ceftazidime combination commences phase II clinical trial in hospital patients with complicated urinary tract infections. Press release 2008 Nov 12 [online]. Available from URL: http://www.novexel.com/includes/cms/_contenus/mod_press_releases/CP_1211_2008.pdf. [Accessed 2009 Feb 23]